secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-152866
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Therapeutics launches underwritten public offering, suspends ATM sales
-------------------------------------------------------------------------------

- Company announced proposed underwritten public offering of common stock on April 13, 2026.
- Sales under existing ATM agreement with TD Securities are suspended pending new prospectus.
- No offering size or pricing details disclosed in the 8-K; further supplement expected.
- Proceeds intended for general corporate purposes; dilution to existing shareholders anticipated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000119312526152866/0001193125-26-152866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000119312526152866/d249901d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-152866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer